
Microglia-mediated neuroinflammation is a key contributor to secondary brain injury across diverse cerebrovascular pathologies, yet the precise transcriptomic diversity and temporal evolution of microglial states across different stroke subtypes remain to be fully elucidated. We utilized single-cell RNA sequencing to profile the temporal transcriptomic landscape of the immune microenvironment in mouse models of ischemic stroke (IS), hemorrhagic stroke (HS), and chronic cerebral hypoperfusion (CCH) at 3, 7 and 14 days post-injury. Our data showed a "temporal mismatch" in immunological trajectories between acute and chronic insults. Specifically, IS and HS triggered an immediate, burst-like microglial activation as early as 3 days, the CCH model exhibited a significant latency window, maintaining a predominantly homeostatic profile until a profound transcriptomic transition toward active phenotypes occurred at 14 days. Notably, we identified a prominent S100A8+/CHIL3+ inflammatory cluster enriched during the hyperacute phase of HS, which may represent an early inflammatory signature associated with intraparenchymal hemorrhage. Interestingly, despite these early divergent responses, the 14-day microglial landscapes across the three models showed a putative shared chronic activation pattern characterized by SPP1+ DAM-like signatures and MHC-II-associated antigenpresentation features. Furthermore, we identified a pre-existing stress-responsive signature (Hspa1a+/ Hspa1b+) in steady-state white matter microglia. These findings provide a high-resolution roadmap of the divergent and convergent immune signatures across cerebrovascular disease spectra, offering hypothesis-generating insights for the development of stage-specific and etiology-tailored immunotherapeutic interventions. Overall, our pooled-library scRNA-seq analysis provides a descriptive and hypothesis-generating framework for strokeassociated microglial and supported by selected tissue-level validation.
Aging is a potent risk factor for poor prognosis in subarachnoid hemorrhage (SAH), yet the molecular mechanisms underlying the age-related exacerbation of early brain injury remain incompletely understood. This study investigates the immunometabolic regulation of the microglial senescence-like transition following SAH, focusing on the immune-responsive gene 1 (IRG1)/itaconate axis. We observed that the endogenous upregulation of IRG1 and itaconate is a protective response to hemorrhagic stress that is significantly blunted in aged mice. Microglia-specific IRG1 deficiency exacerbated SAH-induced brain injury, characterized by an accelerated senescence-like transition and the secretion of senescence-associated secretory phenotype (SASP) factors. Mechanistically, we demonstrate that IRG1 deficiency leads to excessive mitochondrial fission and dysfunction via the hyperactivity of Dynamin-related protein 1 (Drp1). Using click chemistry-based proteomics and site-directed mutagenesis, we identified that itaconate exerts its neuroprotective effects by directly alkylating the small GTPase RhoA at the cysteine 107 (C107) residue. This specific post-translational modification inhibits RhoA-GTP binding and downstream ROCK1 activation, thereby suppressing Drp1-mediated mitochondrial fragmentation. Importantly, treatment with the cell-permeable itaconate derivative 4-octyl itaconate (4-OI) rescued mitochondrial dynamics and attenuated microglial senescence and neurological deficits, whereas the RhoA-C107S mutation abolished these protective effects. Collectively, our findings unveil a novel metabolic-mitochondrial checkpoint involving the IRG1/itaconate-RhoA-Drp1 axis. Restoring this pathway represents a promising therapeutic strategy to combat the age-related exacerbation of neuroinflammation and improve outcomes in SAH patients.
Cellular senescence drives inflammation and fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD) through the senescence-associated secretory phenotype (SASP). Existing research covers hepatocyte types, SASP signaling pathways, and senescence-targeting drugs. However, basic mechanistic understanding and precise clinical translation remain disconnected. An integrative therapeutic framework that couples senescence heterogeneity with disease stage-specific microenvironmental contexts is still lacking. This Perspective presents a hypothesis-generating translational framework and a candidate sequential trial design. The proposed sequence would combine short-term senescent cell clearance with long-term senescence modulation and metabolic maintenance. By stratifying senescence biomarkers according to clinical decision functions into patient selection markers, treatment timing markers, and response efficacy markers, and by defining candidate therapeutic windows based on disease stages, this study proposes lifestyle intervention and senescence modulation as proposed preventive strategies during simple steatosis, the testing of short-term senescent cell clearance during metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis within prospective trial settings, and careful evaluation of intervention feasibility and anticipated benefits under strict risk stratification during cirrhosis. Patients with active hepatocellular carcinoma or high-risk premalignant lesions should currently be excluded from early senolytic trials pending dedicated safety data, rather than being described as an absolute clinical contraindication. This work aims to provide an actionable and verifiable reference framework for precise translation of senescence-targeted therapy in MASLD, moving the field from whether it works toward for whom it works, when it works, and how to test it safely and effectively. All proposed thresholds, strategies, and sequences are candidate endpoints for prospective validation.
Whether the loss of adult hippocampal newborn neuron (NBN) function contributes to Alzheimer's disease (AD) amyloid pathology remains unclear. Adult NBNs regulate dentate gyrus (DG) circuitry, and their decline has been observed during AD progression. To investigate their role, we generated NBN-APP mice by crossing APPswe/PS1dE9 mice with NBN-TeTX mice. Importantly, in vivo microdialysis in the DG molecular layer prior to plaque formation demonstrated that the loss of NBN function for 4 weeks, starting at 3 months of age (early phase), elevated soluble A beta levels (p < 0.001). At this early phase, we also observed increased A beta deposition in the lateral entorhinal cortex (p < 0.001). Furthermore, to evaluate chronic cumulative pathology, we extended the loss of NBN function to 8 weeks starting at 5 months of age (late phase), which resulted in enhanced A beta plaque deposition in the DG molecular layer, widespread glial activation and inflammatory responses throughout the hippocampus, alongside cognitive alterations. Together, these findings demonstrate that the loss of NBN function consistently induces A beta accumulation across both early and late phases, and is associated with glial activation, highlighting its contribution to AD pathology.
Alzheimer's disease (AD) is characterized by amyloid-beta (AR) accumulation, neuroinflammation and cognitive impairment. During AD pathogenesis, AR undergoes several post-translational modifications, the most common of which is the isomerization of aspartic acid (isoD7-AR), a modification that contributes to the disease development. Passive immunization with isoD7-AR-specific antibodies reduced cognitive impairment and amyloid deposition in 5xFAD mice. However, therapeutic application of anti-AR antibodies has important limitations, emphasizing the need for alternative approaches. Here, we evaluated the efficacy of isoD7-AR1-16-targeting immunization compared with AR1-16-targeting immunization on AD pathogenesis in APP/PS1 mice. Both isoD7-AR1-16 and AR1-16, conjugated with ovalbumin, induced AR1-16-specific memory B cells and IgG in mice. However, only isoD7-AR1-16 conjugate promoted B cell and IgG response to the neoepitopes on isoD7-AR1-16. In the Y-maze test, only APP/PS1 mice immunized with isoD7-AR1-16 at 3 months of age retained spatial memory as they aged, in contrast to APP/PS1 mice immunized with AR1-16 at the same age. Immunization with both isoD7-AR1-16 and AR1-16 significantly reduced amyloid burden, lowered microglial and astrocyte activation. Furthermore, we assessed the effect of immunization in APP/PS1 mice at a later stage of AD pathogenesis, at 6 months of age. Even at the stage of advanced disease, immunization with isoD7-AR1-16 strongly impeded the formation of amyloid plaques and reduced brain-wide microglial and astrocyte activation, in contrast to immunization with AR1-16. Our results indicate the promise of targeting isoD7-AR for active AD immunotherapy, both for preventing the development of the pathology at its early stage and for ceasing the advanced AD pathogenesis.